

1     **Title**

2     A multicenter study to assess the performance of the point-of-care RT-PCR Cobas SARS-CoV-  
3     2 & Influenza A/B nucleic acid test for use on the Cobas Liat system in comparison with  
4     centralized assays across healthcare facilities in the United States

5

6     **Authors**

7     Elissa M. Robbins<sup>a#</sup>

8     Rasa Bertuzis<sup>a</sup>

9     Ho-Chen Chiu<sup>b</sup>

10    Lupe Miller<sup>a</sup>

11    Christopher Noutsios<sup>a</sup>

12

13    **Affiliations**

14    <sup>a</sup>Roche Molecular Systems, Inc., Pleasanton, California, USA

15    <sup>b</sup>Roche Sequencing Solutions, Inc., Indianapolis, Indiana, USA

16

17    <sup>#</sup>**Corresponding author**

18    Elissa M. Robbins

19

20    **Running title**

21    Cobas Liat SARS-CoV-2 & Influenza A/B test

## 22 **Non-structured abstract**

23 Respiratory diseases can share many of the same symptoms, highlighting the need for  
24 timely and accurate differentiation to facilitate effective clinical management and reduce  
25 transmission. Compared with centralized testing, molecular point-of-care tests (POCT) can  
26 provide a faster time to result.

27 We evaluated the RT-PCR POCT Cobas<sup>®</sup> SARS-CoV-2 & Influenza A/B qualitative assay for  
28 use on the Cobas Liat<sup>®</sup> system (the Cobas Liat SARS-CoV-2 & Influenza A/B test) in nasal  
29 and nasopharyngeal swab samples from 10 diverse healthcare facilities in the US. A  
30 composite comparator design consisting of three centralized tests was used to analyze  
31 SARS-CoV-2, whilst performance versus a single centralized test was used for analysis of  
32 influenza A and B. Evaluations included performance stratified by sample type  
33 (prospective/retrospective and nasal/nasopharyngeal [paired by subject]), collection method  
34 (self/healthcare worker-collected [alternated and approximately balanced], symptom status  
35 (symptomatic/asymptomatic), and SARS-CoV-2 vaccination status, as well as assay  
36 inclusivity and system ease of use.

37 A total of 2,247 samples were tested. For SARS-CoV-2, the overall percent agreement (OPA)  
38 was 98.8% (95% CI: 97.9, 99.3) in nasal swab samples and 99.0% (95% CI: 98.2, 99.4) in  
39 nasopharyngeal swab samples. Regression analysis showed that Ct values from paired nasal  
40 and nasopharyngeal swab samples were highly correlated (correlation coefficient 0.83). The  
41 OPA was  $\geq 99.5\%$  (sample type dependent) and 100.0% for influenza A and B, respectively.  
42 The Cobas Liat SARS-CoV-2 & Influenza A/B test was easy to use.

43 These results support the use of the POCT in various sample types and by various operators  
44 in the intended-use setting.

## 45 **Summary statement/importance**

46 This study highlights the benefits of RT-PCR POCT, namely comparable performance to  
47 centralized testing in multiple sample types and ease of use. Utilizing assays such as the  
48 Cobas Liat SARS-CoV-2 & Influenza A/B test may improve timely differentiation of  
49 respiratory diseases that share similar symptoms.

## 50 **Introduction**

51 More than 4 years since the start of the coronavirus disease 2019 (COVID-19) pandemic,  
52 much of the world has returned to normality, yet COVID-19 continues to cause severe illness  
53 and mortality in the United States (US) and elsewhere(1, 2). This applies particularly for the  
54 immunocompromised, who are at risk of severe outcomes (3) and comprise approximately  
55 3% of the US adult population(4). Disease activity is year-round, but seasonal spikes occur  
56 from November to April(5), coinciding with circulation of other respiratory viruses, such as  
57 influenza(6). Respiratory diseases such as COVID-19 and influenza share similar  
58 symptoms(7), highlighting the need for timely and accurate differentiation of the causative  
59 agent to help facilitate effective clinical management and reduce onward transmission.

60 The current choice of testing for severe acute respiratory syndrome coronavirus 2 (SARS-  
61 CoV-2) is setting dependent(8), but standard laboratory-based (i.e., centralized) nucleic acid  
62 amplification tests are the mainstay of diagnosis(9). Numerous antigen or molecular point-  
63 of-care tests (POCT) are commercially available(10, 11), offering the benefit of a faster time  
64 to result(12). Both POCT formats have lower performance compared with centralized  
65 testing, particularly sensitivity (13) — a secondary analysis of antigen POCT found the  
66 performance to be commonly lower than stated within manufacturers' instructions for use  
67 (14) — but molecular POCT have relatively higher performance in comparison with antigen  
68 POCT, with pooled sensitivity values of 93% (99% specificity) versus 71% (99% specificity),  
69 respectively(13). Molecular POCT can provide actionable results in as little as 20 minutes  
70 depending on the assay and workflow(11).

71 Influenza is a significant cause of severe illness and death(15-17), resulting in a substantial  
 72 clinical burden to patients and the healthcare system alike(18). Molecular POCT for the  
 73 detection of influenza A/B subtypes, and other respiratory viruses such as respiratory  
 74 syncytial virus, have been available for several years(11, 12, 19-22). Clinical practice  
 75 guidelines from the Infectious Diseases Society of America recommend that antivirals are  
 76 initiated for certain patient groups as soon as possible regardless of illness duration, or  
 77 within 48 hours of illness onset(23), supporting the use of rapid molecular POCT for  
 78 influenza testing in preference to centralized laboratory testing. In the hospital setting, an  
 79 interventional study of a molecular POCT for influenza found significant improvements in  
 80 isolation practices and reductions in length of stay compared with centralized testing(24),  
 81 whilst a modeling study found that the introduction of POCT could reduce time to diagnosis,  
 82 hospital stay, and in-hospital costs(25). Molecular POCT for influenza can generate sensitivity  
 83 estimates of  $\geq 96$ –100% in real-world settings(22, 26).

84 The primary objective of this study was to evaluate the real-world clinical performance of  
 85 the POC Cobas SARS-CoV-2 & Influenza A/B qualitative assay for use on the Cobas Liat  
 86 system (herein referred to as the Cobas Liat SARS-CoV-2 & Influenza A/B test), a  
 87 multiplexed RT-PCR test combining measurement of SARS-CoV-2 and influenza subtypes, in  
 88 reference to comparator centralized PCR tests for SARS-CoV-2 and influenza A and B viruses.  
 89 Sample types were nasal and nasopharyngeal swab specimens from individuals suspected of  
 90 respiratory viral infection consistent with COVID-19, and asymptomatic individuals exposed  
 91 to COVID-19, who presented at healthcare facilities across the US during the COVID-19  
 92 public health emergency. Secondary objectives were to evaluate the influence of collection  
 93 method and the ease of use of the Cobas Liat system.

## 94 **Materials and methods**

### 95 **Sites**

96 Testing was conducted at 11 sites: 10 geographically diverse healthcare facilities that were  
 97 representative of intended-use sites (i.e., POC settings, such as emergency departments,  
 98 urgent care, pediatric and primary care clinics, and drive-through COVID-19 testing sites),  
 99 and one reference laboratory for centralized testing. After testing using the Cobas Liat SARS-  
 100 CoV-2 & Influenza A/B test at the healthcare facilities, samples were shipped to the  
 101 reference laboratory for analysis with the comparator assays (see below).

102 Healthcare facilities were selected based on sample availability, ability to provide adequate  
 103 resources and operators, ability to adhere to good clinical practice, and with the aim of  
 104 ensuring representation of the demographic diversity of the US population. Not all  
 105 healthcare facilities performing testing were certified under Clinical Laboratory Improvement  
 106 Amendments (CLIA) regulations to perform waived testing, but all facilities met the  
 107 requirements for CLIA-waived settings (i.e., intended-use settings using untrained non-  
 108 laboratory personnel). All healthcare facilities performed both sample collection and POC  
 109 testing. POC operators at the 10 healthcare facilities (n=30 operators in total) had limited or  
 110 no laboratory training and were representative of typical test operators in CLIA-waived  
 111 settings (e.g., nurses, nursing assistants, and medical assistants). Operators at the reference  
 112 laboratory were blinded to the results generated at the healthcare facilities.

### 113 **Study population**

114 The symptomatic group comprised samples from individuals with suspected respiratory viral  
 115 infection consistent with COVID-19 (see Signs/symptoms, Supplementary material). The  
 116 asymptomatic group comprised individuals with self-reported 'recent' exposure (timeframe  
 117 undefined) to SARS-CoV-2-positive individuals or any other reasons to suspect COVID-19.  
 118 Patient clinical information was gathered, including, but not limited to, antiviral usage for up

to 7 days prior to and on the day of sample collection, gender, race/ethnic group, and age. Individuals presenting at the healthcare facilities were considered for study inclusion, subject to the eligibility criteria (see Eligibility criteria, Supplementary material).

## **Study design**

The clinical performance of the POC Cobas Liat SARS-CoV-2 & Influenza A/B test (27) was evaluated by comparing results to a composite comparator method for the SARS-CoV-2 analyte using the following three highly sensitive centralized testing assays: Cobas SARS-CoV-2 qualitative assay for use on the Cobas 6800/8800 systems (herein referred to as the Cobas 6800/8800 SARS-CoV-2 test)(28); Cobas SARS-CoV-2 & Influenza A/B qualitative assay for use on the Cobas 6800/8800 systems (herein referred to as the Cobas 6800/8800 SARS-CoV-2 & Influenza A/B test)(29); and Hologic® Aptima® SARS-CoV-2 Assay(30).

The clinical performance for the influenza A/B analyte components of the Cobas Liat SARS-CoV-2 & Influenza A/B test was evaluated against a single centralized testing assay, the Cobas 6800/8800 SARS-CoV-2 & Influenza A/B test(29).

Samples that generated invalid results were repeated where sample volume permitted additional testing; samples generating a second invalid result upon retesting were reported as invalid. Interrogation of discrepant samples was not performed, though selected samples were further retested with the Cobas Liat SARS-CoV-2 & Influenza A/B test for exploratory purposes.

## **Sample types and collection**

Sample types included fresh and frozen nasal and nasopharyngeal swab samples, collected in the same media formulations but under different brand names: Copan Universal Transport Medium (UTM) or BD Universal Viral Transport (UVT) medium.

## Prospective fresh samples (UTM)

One nasal swab and one nasopharyngeal swab sample were collected from each study participant. A nasal swab of both nostrils was first collected either by the healthcare worker (HCW), herein referred to as 'HCW-collected', or by the study participant under instruction from the HCW, herein referred to as 'self-collected', as per manufacturer's instructions.(31) A nasopharyngeal swab was then collected by HCWs from the same study participant to generate paired samples. If a nasopharyngeal swab had already been collected (using one nostril) as part of the healthcare facility's standard of care, the study nasopharyngeal swab was taken from the opposite nostril.

All prospective samples were collected from patients presenting to healthcare facilities during February to June 2022, characteristic of the 2021/2022 winter respiratory season.

## Retrospective frozen samples (archived or purchased from external vendors; UTM or UVT)

The low influenza prevalence in the prospective population was anticipated because of reduced international travel, new respiratory care paradigms, increased public health awareness, and use of interventions (such as masking policies or social distancing) that occurred during the COVID-19 pandemic and study enrollment period, in which influenza A virus had been the dominant virus type in circulation.(32) Therefore, frozen samples positive for influenza A virus and for influenza B virus were used to supplement the prospectively collected fresh samples. These retrospective samples were collected in the US during the 2013–2014, 2014–2015, and 2019–2020 influenza seasons. Baseline demographic data and patient characteristics related to these samples were unavailable.

Retrospective samples with known SARS-CoV-2 status, collected between March 29, 2021 and May 26, 2021, were also included in the SARS-CoV-2 analyses.

Whilst multiple freeze-thaw cycles have a limited effect on the viral titer(33), there is the potential for samples that were initially low-titer positives to appear negative following storage. Internal Roche data support the stability of viral titer for up to three freeze-thaw cycles, so retrospective samples were only eligible for inclusion if they had undergone no more than two freeze-thaw cycles. Retrospective positive and negative samples were blended in a standard POCT workflow and assessed alongside prospectively collected samples.

## **Details of assays and instruments**

### Cobas Liat SARS-CoV-2 & Influenza A/B test (POC RT-PCR)

The Cobas Liat analyzer is for *in vitro* diagnostic use(27). The analyzer automates all nucleic acid amplification test processes, including target enrichment, inhibitor removal, nucleic acid extraction, reverse transcription, DNA amplification, real-time detection, and result interpretation in approximately 20 minutes(27). The Cobas Liat system comprises the Cobas Liat analyzer in conjunction with the Cobas Liat assay tubes(27).

The Cobas Liat SARS-CoV-2 & Influenza A/B test utilizes a single-use disposable assay tube that contains all the reagents necessary for the detection of SARS-CoV-2 and hosts the sample preparation and PCR processes(34). This multiplex real-time RT-PCR test is intended for the simultaneous rapid *in vitro* qualitative detection and differentiation of SARS-CoV-2, influenza A, and influenza B virus RNA in healthcare provider-collected nasal and nasopharyngeal swab samples and self-collected nasal swab samples (collected in a healthcare setting with instruction by a healthcare provider) from individuals suspected of respiratory viral infection consistent with COVID-19(34).



# 187 Cobas 6800/8800 SARS-CoV-2 & Influenza A/B test (centralized testing method [CTM] 1)

188 The Cobas 6800/8800 systems consists of the sample supply module, the transfer module,  
189 the processing module, and the analytic module(29). Automated data management is  
190 performed by the Cobas 6800/8800 software, which assigns results for all tests. Results are  
191 available within less than 3.5 hours after loading the sample on the system.(29) The positive  
192 SARS-CoV-2 result is defined as positive on the SARS-CoV-2 channel (Target 2) and/or the  
193 pan-sarbeco channel (Target 3).

194 The Cobas 6800/8800 SARS-CoV-2 & Influenza A/B test is an automated multiplex real-time  
195 RT-PCR assay intended for simultaneous qualitative detection and differentiation of SARS-  
196 CoV-2, influenza A virus, and/or influenza B virus RNA in healthcare provider-collected nasal  
197 and nasopharyngeal swab samples and self-collected nasal swab samples (collected in a  
198 healthcare setting with instruction by a healthcare provider) from individuals suspected of  
199 respiratory viral infection consistent with COVID-19(29).

## 200 Cobas 6800/8800 SARS-CoV-2 test (CTM 2)

201 The Cobas 6800/8800 SARS-CoV-2 test is an automated real-time RT-PCR assay intended for  
202 the qualitative detection of nucleic acids from SARS-CoV-2 in healthcare provider-instructed,  
203 self-collected anterior nasal (nasal) swab samples (collected onsite) and healthcare provider-  
204 collected nasal, nasopharyngeal, and oropharyngeal swab samples collected from any  
205 individuals, including those suspected of COVID-19 by their healthcare provider, and those  
206 without symptoms or with other reasons to suspect COVID-19(28). The positive SARS-CoV-2  
207 result is defined as positive on the SARS-CoV-2 channel (Target 1) and/or the pan-sarbeco  
208 channel (Target 2).

## 209 Hologic Aptima SARS-CoV-2 assay (tiebreaker; CTM 3)

210 As a commonly used molecular assay(30), CTM 3 was utilized as a tiebreaker. The test  
211 utilizes transcription-mediated amplification for the qualitative detection of RNA from SARS-  
212 CoV-2 isolated and purified from nasopharyngeal, nasal, mid-turbinate and oropharyngeal  
213 swab samples, nasopharyngeal wash/aspirate, or nasal aspirates obtained from individuals  
214 meeting COVID-19 clinical and/or epidemiological criteria(35).

## 215 **Analyses**

216 All data analyses were performed using SAS/STAT® software (v9.4 or higher of the SAS  
217 System for Linux). No formal sample size calculations were calculated for this study, but  
218 patient enrollment was adjusted to accommodate disease prevalence and to generate a  
219 minimum of 50 SARS-CoV-2 positives, 30 influenza A positives, and 10 influenza B positives  
220 for analysis.

221 The clinical performance of the Cobas Liat SARS-CoV-2 & Influenza A/B test was evaluated  
222 using estimates of positive percent agreement (PPA), negative percent agreement (NPA),  
223 and overall percent agreement (OPA), calculated with 2-sided 95% confidence intervals (CI)  
224 using the Wilson-score method(36). Comparison was against either the composite  
225 comparator for SARS-CoV-2 (CTM 1, CTM 2, and CTM 3 [tiebreaker if required]) or a single  
226 comparator for influenza A/B (CTM 1).

227 For SARS-CoV-2, concordant results from CTM 1 and CTM 2 established true positive or true  
228 negative status. In the event of discordance between CTM 1 and CTM 2, CTM 3 (the  
229 tiebreaker) was used to establish true status. Samples could be coded as uninterpretable in  
230 the event of invalid, failed, aborted or missing results that were not resolved upon retesting.  
231 If CTM 1 or CTM 2 or CTM 3 returned uninterpretable results, and the other two methods  
232 returned different results (i.e., CTM 1 positive, CTM 2 negative, and CTM 3 uninterpretable),  
233 then the status of the sample would be described as indeterminate.

McNemar's mid-p test (P-value) was used to assess any differences between sample types. A P-value of <0.05 was considered statistically significant.

POCT operators were asked to complete a questionnaire to evaluate the ease of use of the Cobas Liat SARS-CoV-2 & Influenza A/B test.

*In silico* analysis of the Cobas Liat SARS-CoV-2 & Influenza A/B test was performed to assess assay design inclusivity on all available SARS-CoV-2 sequences (taxonomy ID 2697049) in the Global Initiative on Sharing All Influenza Data (GISAID) and National Center for Biotechnology Information (NCBI) databases up to July 2024 (>16,800,000 sequences in NCBI and >8,900,000 sequences in GISAID). The predicted impact of each variant on gene target 1 and gene target 2 primer and probe binding site sequence was evaluated using Roche proprietary software and Melting5 software. A SARS-CoV-2 sequence would be potentially not detected by the Cobas Liat SARS-CoV-2 & Influenza A/B test if a delay in cycle threshold greater than five cycles and/or a probe melting temperature of <65°C was predicted.

## **Ethics statement**

This study was a non-interventional evaluation of an *in vitro* diagnostic device (test results were not used to inform patient care decisions). This study was conducted in compliance with International Conference on Harmonisation Good Clinical Practice guidelines, regulations of the US Food and Drug Administration (FDA), and the Declaration of Helsinki. The study protocol was submitted to Institutional Review Boards (IRBs) in accordance with FDA and local regulatory requirements before the start of the study. The following IRBs gave permission for this study to be performed: NorthShore University Health System Institutional Review Board; University of Rochester, Research Subjects Review Board; and Western IRB.

## **Results**

## Participants and summary of testing results

Subjects from 10 geographically diverse healthcare facilities were enrolled in the study. The summary of testing results can be seen in **Supplemental Table A**. A total of 2,209 SARS-CoV-2 results from prospective samples (both nasal and nasopharyngeal swabs) were valid for inclusion in downstream analyses.

## Population and baseline characteristics

Baseline demographic data for study participants were available for the prospectively collected samples; details on the study participants are presented in **Table 1**. Of these subjects, 506 were male (47.8%) and 553 were female (52.2%). The median age was 35 years (range 0–86).

Patient characteristics are present in **Supplemental Table B**. In total, 60.4% of subjects in the prospective population had signs and symptoms of respiratory infection, with days from onset of first symptom ranging from 1 to 365 days. The remaining 39.6% of subjects were asymptomatic but were clinically suspected of SARS-CoV-2 infection by their healthcare provider due to recent exposure or other reason. The nasal swab samples were evenly distributed between HCW-collected and self-collected.

## Medical history

The medical history relating to vaccination status is presented in **Table 2**. Most participants received a COVID-19 vaccine (68.7%), with Pfizer as the most common vaccine for both first and second doses (69.5% and 72.2%, respectively).

## SARS-CoV-2

### Determination of the composite comparator status for SARS-CoV-2

In symptomatic study participants, the composite comparator method was SARS-CoV-2 positive for 134 nasal and 131 nasopharyngeal swab samples (**Supplemental Table C**).

In asymptomatic study participants, the composite comparator method was SARS-CoV-2 positive for 39 nasal and 39 nasopharyngeal swab samples (**Supplemental Table C**).

#### Performance

The total number of samples that were positive, negative, or invalid, and how these align with the composite comparator status, can be seen in **Figure 1**. The diagnostic performance (total number of positive and negative results) for SARS-CoV-2 can be seen in **Table 3**.

Agreement between the composite comparator and the Cobas Liat SARS-CoV-2 & Influenza A/B test for detection of SARS-CoV-2 in nasal swabs (total, prospective and retrospective, self-collected or HCW-collected), nasopharyngeal swabs (total, prospective and retrospective), in samples from vaccinated and unvaccinated participants, and in symptomatic and asymptomatic participants can be seen in **Supplemental Table D**. For nasal swab samples, the total OPA, PPA, and NPA was 98.8% (95% CI: 97.9, 99.3), 97.1% (95% CI: 93.3, 98.7), and 99.1% (95% CI: 98.2, 99.5), respectively. Of note, the OPA for HCW-collected nasal swab samples was 98.4% (95% CI: 97.0, 99.2) and 99.1% (95% CI: 98.0, 99.6) for self-collected nasal swab samples. The total OPA, PPA, and NPA for nasopharyngeal swab samples was 99.0% (95% CI: 98.2, 99.4), 96.4% (95% CI: 92.4, 98.4), and 99.4% (95% CI: 98.7, 99.8), respectively.

Using all paired results for nasal and nasopharyngeal swab samples by subject, the swab type did not make a difference in the reported result (McNemar's mid-p test,  $P=0.771$ ).

#### Cycle threshold (Ct) value distributions

The range of Ct values in nasal and nasopharyngeal swab samples can be seen in **Figure 2**. Self-collected nasal swabs showed the highest average viral load followed by nasopharyngeal swabs, then HCW-collected nasal swabs.

The range of Ct values in subject-paired nasal and nasopharyngeal swab samples can be seen in **Figure 3**. The Deming regression analysis showed that the two sample types were highly correlated (**Figure 3A**;  $r = 0.83$ ). Exploration of the collection method showed that HCW-collected nasal swabs had greater concordance between the paired samples (**Figure 3B**;  $r = 0.91$ ) than the self-collected nasal swabs ( $r = 0.77$ ; **Figure 3C**).

#### Discordance

Fourteen nasal and 11 nasopharyngeal swab samples showed discordant results between the Cobas Liat SARS-CoV-2 & Influenza A/B test and the centralized testing methods (**Supplemental Table E**); 10 were positive only on the Cobas Liat SARS-CoV-2 & Influenza A/B test.

#### **Influenza A**

##### Performance

The agreement between the Cobas Liat SARS-CoV-2 & Influenza A/B test and the Cobas 6800/8800 SARS-CoV-2 & Influenza A/B test for detection of influenza A in nasopharyngeal swabs (total, prospective and retrospective) and nasal swabs (total, prospective and retrospective, HCW-collected or self-collected) can be seen in **Supplemental Table F**. The OPA ranged from 98.9% to 100.0%.

##### Discordance

Two nasal and five nasopharyngeal swab samples showed discordant results between the Cobas Liat SARS-CoV-2 & Influenza A/B test and the Cobas 6800/8800 SARS-CoV-2 & Influenza A/B test for detection of influenza A (**Supplemental Table G**), four of which were positive only on the Cobas Liat SARS-CoV-2 & Influenza A/B test.

#### **Influenza B**

## 328 Performance

329 The agreement between the Cobas Liat SARS-CoV-2 & Influenza A/B test and the Cobas  
330 6800/8800 SARS-CoV-2 & Influenza A/B test for detection of influenza B in nasopharyngeal  
331 swabs (total, prospective and retrospective) and nasal swabs (total, prospective and  
332 retrospective, self-collected nasal or HCW-collected) can be seen in **Supplemental Table**  
333 **H**. The OPA for all comparisons was 100.0%.

## 334 Discordance

335 No discordant results between the Cobas Liat SARS-CoV-2 & Influenza A/B test and the  
336 Cobas 6800/8800 SARS-CoV-2 & Influenza A/B test for detection of influenza B were  
337 recorded.

## 338 **Evaluation of the ease of use for the Cobas Liat system**

339 Twenty-seven operators with experience of testing samples on the Cobas Liat completed the  
340 questionnaire. The operators' average scores indicating their agreement with the statements  
341 in the questionnaire are shown in **Supplemental Table I**. The overall score was 4.5 out of  
342 5 for the operators' answers to all eight statements, indicating that the operators agreed  
343 that the Cobas Liat system was easy to use.

## 344 **Inclusivity analysis**

345 The Cobas Liat SARS-CoV-2 & Influenza A/B test targets the nucleocapsid (N) and ORF1a/b  
346 regions of the SARS-CoV-2 genome.(34) *In silico* analysis showed that 99.98% of NCBI and  
347 99.99% of GISAID sequences for SARS-CoV-2 had no changes in the primer/probe binding  
348 sites of both target regions simultaneously. All sequences were predicted to be detected by  
349 at least one of the two sites.

## 350 **Discussion**

In this study, we evaluated the performance of the POC RT-PCR Cobas Liat SARS-CoV-2 & Influenza A/B test against up to three centralized assays, stratified by various parameters. The high performance of the Cobas Liat SARS-CoV-2 & Influenza A/B test in comparison with centralized testing methods utilizing nasopharyngeal or nasal samples has previously been reported(37-41), but this study is the first to report the performance of the Cobas Liat SARS-CoV-2 & Influenza A/B test across variables such as collection method (self/HCW, retrospective/prospective), vaccination status, symptom status, and ease of use. Using the comparator result to establish the status of infection, we found high agreement between the POC RT-PCR test and the centralized testing assays for all three analytes across all variables. Previously, a meta-analysis of nucleic acid amplification testing reported that the sensitivity for detection of SARS-CoV-2 in nasal samples may be less than nasopharyngeal samples(42), whilst a study specifically assessing the Cobas Liat SARS-CoV-2 & Influenza A/B test reported similar differences in SARS-CoV-2 detection by sample type(37). However, we saw no evidence of a sample-type difference in sensitivity, with SARS-CoV-2 positivity identified in both nasal and nasopharyngeal swab samples to a similar extent (Cobas Liat SARS-CoV-2 & Influenza A/B test positivity rate approximately 15%; the difference in sensitivity [nasal minus nasopharyngeal] was +0.9%).

A small study from Denmark found almost equivalent sensitivity for detection of SARS-CoV-2 using self- and HCW-collected samples (84.2% vs 89.5%, respectively), and that patients preferred self-collection(43). In our study, whether nasal samples were collected by HCWs or by the patients themselves had little impact on the agreement values between the POC RT-PCR test and the comparators. Indeed, in all comparisons the agreement for self-collected samples was actually higher than for HCW-collected samples. For SARS-CoV-2, Ct values of paired nasal and nasopharyngeal swab samples as measured by the POC RT-PCR test were highly correlated, and Ct values were on average lower in nasal swab samples (i.e., higher viral RNA titer) compared with nasopharyngeal swab samples, with self-collected nasal



swabs exhibiting the lowest Ct values. Collectively, this indicates that the high performance level of the POC RT-PCR test is maintained across collection methods, and that patients are able to self-sample effectively, and are willing to do so.

We identified a small number of discrepant samples for the SARS-CoV-2 analyte in both nasal and nasopharyngeal swab samples, consistent with other studies(37, 38), most of which were false positives. The majority of the false positives were in the high Ct/low viral titer range (Cobas Liat SARS-CoV-2 & Influenza A/B test Ct values: lowest 28.2, median 35.2, highest 37.1) and thus close to or at the lower limit of detection of Ct 35.2 (USA-WA1/2020 strain) for the Cobas Liat SARS-CoV-2 & Influenza A/B test(34). Of the false negatives detected by the Cobas Liat SARS-CoV-2 & Influenza A/B test, all except one sample were in the high Ct range. Indeed, after exploratory re-testing of false-negative nasopharyngeal samples, two were found to be positive (re-tested Ct values were 34.8 and 35.4). Generally, low viral burden can be a cause of discrepant results(44), and a small external quality assessment (reproducibility) study reported that the performance of the Cobas Liat SARS-CoV-2 & Influenza A/B test is highest at low Ct values(45).

US legislation categorizes tests for complexity (moderate or high) using seven criteria, such as the need for training and experience, and assigns scores within each criterion(45). Test systems can be assigned as 'waived complexity' under certain conditions, and these tests require no formal operator training or competency(45). In addition to CLIA-certified laboratories, the Cobas Liat SARS-CoV-2 & Influenza A/B test is authorized for use in patient care settings that are CLIA waived(34). In conjunction with the fast turnaround offered by the Cobas Liat system and demonstrated in studies of the Cobas Liat SARS-CoV-2 & Influenza A/B test in real-world settings (40, 46) or studies evaluating workflow or processing time(41, 47), our study confirms that the Cobas Liat SARS-CoV-2 & Influenza A/B test is easy to use in CLIA-waived settings, and offers results in a timeframe conducive for rapid patient management.

The strength of our multicenter study lies in the comprehensive nature of the variables assessed, encompassing a wide variety of patient characteristics likely to be encountered in healthcare settings. The study included a prospectively enrolled cohort of patients seeking care, which is representative of the intended-use population of the Cobas Liat SARS-CoV-2 & Influenza A/B test. Our study has some limitations. Firstly, we did not ascertain the SARS-CoV-2 variants present in the samples. Whilst the emergence of SARS-CoV-2 variants has the ability to affect the diagnostic performance of the test, previous studies have indicated that the Cobas Liat SARS-CoV-2 & Influenza A/B test detects both wild-type and variants of concern, such as Alpha (B.1.1.7) or Omicron (B.1.1.529)(39, 47). Bioinformatic analysis to assess inclusivity showed that the Cobas Liat SARS-CoV-2 & Influenza A/B test is predicted to bind all sequences available in the NCBI and GISAID databases as of July 2024. The dual target assay design helps to ensure that the assay is robust and safeguards against the emergence of variants that have the potential to affect assay performance and evade detection.

## **Conclusion**

A POC RT-PCR test combining both measurement of SARS-CoV-2 and influenza subtypes with performance equivalent to routine centralized testing would provide a critical tool to improve the diagnosis and management of COVID-19 and influenza. We found that the performance of the Cobas Liat SARS-CoV-2 & Influenza A/B test was comparable to centralized testing methods. With the ease of use and equivalent performance, it highlights the question as to whether centralized testing should be considered as the gold standard. A study of the Cobas Liat Influenza A/B test (a Liat RT-PCR test that detects only the influenza analyte) in the emergency department found that POC testing for influenza was useful in improving several metrics, including the indication for treatment with neuraminidase in positive cases(48). It is relevant to note that SARS-CoV-2 and influenza coinfection can increase the risk of severe outcomes compared with those infected with SARS-CoV-2 alone,

particularly for those coinfecting with influenza A.(49) Our study highlights the benefits of molecular multiplex POCT to help improve timely differentiation of respiratory diseases that share similar symptoms and support efforts to improve patient management.

## **Funding**

This study was funded by Roche Molecular Systems, Inc (Pleasanton, California, USA).

## **Disclosures**

EMR, RB, HC, LM, and CN are employees of Roche Molecular Systems, Inc. EMR participates in Roche Connect and is a shareholder.

## Assay disclaimers

The Cobas SARS-CoV-2 & Influenza A/B qualitative assay for use on the Cobas Liat system (herein referred to as the Cobas Liat SARS-CoV-2 & Influenza A/B test) was originally approved under Emergency Use Authorization EUA201779 and has since been cleared and Clinical Laboratory Improvement Amendments (CLIA) waived under 223591/CW220014, respectively, in the US and is CE-IVD marked in the European Union. Sample collection in the patient's home is not approved in the US or European Union.

The Cobas SARS-CoV-2 & Influenza A/B qualitative assay for use on the Cobas 6800/8800 systems (herein referred to as the Cobas 6800/8800 SARS-CoV-2 & Influenza A/B test) is authorized only for use under Emergency Use Authorization (EUA) in the US, and is CE-IVD marked in the European Union. The assay is not approved for use in asymptomatic patients in the US or European Union. The assay is not approved for use as a point-of-care (POC) test/near-patient test (NPT) in the US/European Union. Sample collection in the patient's home is not approved in the US or European Union.

The Cobas SARS-CoV-2 qualitative assay for use on the Cobas 6800/8800 systems (herein referred to as the Cobas 6800/8800 SARS-CoV-2 test) is authorized only for use under EUA

in the US, and is CE-IVD marked in the European Union. The assay is not approved for use as a POC test/NPT in the US/European Union. Sample collection in the patient's home is not approved in the US or European Union.

Hologic Aptima SARS-CoV-2 assay is an FDA EUA assay.(30)

## **Data availability**

The datasets generated during and/or analyzed during the current study are not publicly available due to patient confidentiality. Any access requests from qualified researchers should be submitted directly to the Ethical Committee of each participating study site.

## **Acknowledgments**


Medical writing support was provided by Corrinne Segal of Elements Communications Ltd (London, UK) and was funded by Roche Molecular Systems, Inc.

COBAS and LIAT are trademarks of Roche. All other product names and trademarks are the property of their respective owners.

We would like to thank Saima Shams and Vaishali Mody for their contributions to the development of the Cobas SARS-CoV-2 & Influenza A/B qualitative assay for use on the Cobas Liat system (herein referred to as the Cobas Liat SARS-CoV-2 & Influenza A/B test), and Jingtao Sun for his bioinformatics expertise.

## Figures

Figure 1: Detection of SARS-CoV-2 using the Cobas® Liat® SARS-CoV-2 & Influenza A/B test and the composite comparator (prospective and retrospective, symptomatic and asymptomatic subjects)<sup>a</sup>




Abbreviations: CC, composite comparator; POC RT-PCR, point-of-care RT-PCR; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.

<sup>a</sup>The composite comparator comprises the Cobas 6800/8800 SARS-CoV-2 & Influenza A/B test, Cobas 6800/8800 SARS-CoV-2 test, and Hologic® Aptima® SARS-CoV-2 Assay; the POC RT-PCR test is the Cobas Liat SARS-CoV-2 & Influenza A/B test.

The Cobas SARS-CoV-2 & Influenza A/B nucleic acid test for use on the Cobas Liat system is herein referred to as the Cobas Liat SARS-CoV-2 & Influenza A/B test. The Cobas SARS-CoV-2 & Influenza A/B qualitative assay for use on the Cobas 6800/8800 systems is herein referred to as the Cobas 6800/8800 SARS-CoV-2 & Influenza A/B test. Cobas SARS-CoV-2 qualitative assay for use on the Cobas 6800/8800 systems is herein referred to as the Cobas 6800/8800 SARS-CoV-2 test.

Figure 2:  $C_t$  values for the SARS-CoV-2 analyte from the Cobas<sup>®</sup> Liat<sup>®</sup> SARS-CoV-2 & Influenza A/B test in nasal and nasopharyngeal swab samples<sup>a</sup>



Abbreviations: Ct, cycle threshold; HCW, healthcare worker-collected; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.

<sup>a</sup>False positives are represented by black circles. Cross represents mean Ct values. Nasal (total): n=179, mean Ct 23.1, median Ct 21.9,

minimum Ct 11.0, maximum Ct 36.8; HCW-collected nasal: n=87, mean Ct 23.9, median Ct 23.7, minimum Ct 12.3, maximum Ct 36.8; self-

488 collected nasal: n=92, mean Ct 22.4, median Ct 21.1, minimum Ct 11.0, maximum Ct 36.1; nasopharyngeal: n=177, mean Ct 23.4, median Ct  
489 22.8, minimum Ct 10.6, maximum Ct 37.1.

490 False positives are indicated by black circles. The Cobas SARS-CoV-2 & Influenza A/B nucleic acid test for use on the Cobas Liat system is  
491 herein referred to as the Cobas Liat SARS-CoV-2 & Influenza A/B test. Horizontal solid line represents median values. Upper and lower  
492 boundaries of box plot represent 75th and 25th percentile.


493

**Figure 3: Deming regression for the SARS-CoV-2 analyte from the Cobas® Liat® SARS-CoV-2 & Influenza A/B test in subject-paired nasal and nasopharyngeal swab samples<sup>a</sup>**

**A: Nasal (total)**

**B: HCW-collected nasal swab**

**C: Self-collected nasal swab**



Abbreviations: Ct, cycle threshold; FP, false positive; HCW, healthcare worker-collected; NPS, nasopharyngeal swab; NS, nasal; NS FP, nasal false positive; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.

<sup>a</sup>The Cobas SARS-CoV-2 & Influenza A/B nucleic acid test for use on the Cobas Liat system is herein referred to as the Cobas Liat SARS-CoV-2 & Influenza A/B test. Prospective symptomatic = open circle; prospective exposed = triangle. Dashed line represents perfect correlation. Solid line represents Deming regression. Red data points represent HCW-collected nasal swabs. Blue data points represent self-collected nasal swabs.



## 512 Tables

513 Table 1: Demographics (prospective symptomatic and asymptomatic subjects)

Characteristics	Prospective population
<b>Total</b>	
N	1,059
<b>Age (years)</b>	
Mean	34.2
Standard deviation	19.88
Median	35.0
Range (minimum–maximum) <sup>a</sup>	0.0–86.0
<b>Age group (years), n (%)</b>	
≤ 18	287 (27.1)
19–39	319 (30.1)
40–64	391 (36.9)
≥ 65	62 (5.9)
<b>Sex at birth, n (%)</b>	
Male	506 (47.8)
Female	553 (52.2)
<b>Ethnicity, n (%)</b>	
Hispanic/Latino	212 (20.0)
Not Hispanic/not Latino	589 (55.6)
Not reported <sup>b</sup>	236 (22.3)
Unknown <sup>c</sup>	22 (2.1)
<b>Race, n (%)</b>	
American Indian/Alaskan Native	3 (0.3)
Asian	37 (3.5)
Black/African American	175 (16.5)
Native Hawaiian/Pacific Islander	6 (0.6)
White	520 (49.1)
Other	56 (5.3)
Not reported <sup>b</sup>	262 (24.7)

514

515 <sup>a</sup>All subjects <1 year old are counted as age 0.

516 <sup>b</sup>A clinical site that was a mobile drive-through site was not able to collect race/ethnicity  
517 identification from subjects.

518 <sup>c</sup>Unknown category indicates subjects for whom the corresponding information is not  
519 available.

520

521

522 Table 2: Subject medical history (prospective symptomatic and asymptomatic subjects)

523

Characteristics	Population statistics
<b>Total</b>	
N	1,059
<b>Subject received the influenza vaccine within the last 6 weeks, n (%)</b>	
Yes	14 (1.3)
No	1,045 (98.7)
Unknown	0 (0.0)
<b>Influenza vaccine route of administration, n (%)<sup>a</sup></b>	
Intramuscular	14 (100.0)
Intranasal	0 (0.0)
Unknown	0 (0.0)
<b>Subject received a COVID-19 vaccine, n (%)</b>	
Yes	728 (68.7)
No	303 (28.6)
Unknown	28 (2.6)
<b>Type of COVID-19 vaccine received for first dose, n (%)<sup>b</sup></b>	
Pfizer	506 (69.5)
Moderna	185 (25.4)
Johnson & Johnson (J & J)	30 (4.1)
Other	3 (0.4)
Unknown	4 (0.5)
<b>Type of COVID-19 vaccine received for second dose, n (%)<sup>b</sup></b>	
Pfizer	488 (72.2)
Moderna	182 (26.9)
Other	3 (0.4)
Unknown	3 (0.4)
<b>Type of COVID-19 vaccine received first booster, n (%)<sup>b,c</sup></b>	
Pfizer	217 (64.0)
Moderna	115 (33.9)

Characteristics	Population statistics
Johnson & Johnson (J & J)	5 (1.5)
Other	1 (0.3)
Unknown	1 (0.3)

524

525 Abbreviations: COVID-19, coronavirus disease 2019

526 <sup>a</sup>Percentages calculated based on number of subjects who received the influenza vaccine

527 within the last 6 weeks prior to enrollment and sample collection.

528 <sup>b</sup>Percentages calculated based on number of subjects who received COVID-19 vaccine or

529 first booster.

530 <sup>c</sup>There were six subjects that reported receiving a second booster.

531

532

533 Table 3: Results for the detection of SARS-CoV-2 using the composite comparator compared with the Cobas® Liat® SARS-CoV-2 & Influenza  
534 A/B test<sup>a</sup>

	Composite comparator (+)	Composite comparator (-)	Total	PPA % (95% CI)	NPA % (95% CI)
<b>Nasal</b>					
Cobas Liat SARS-CoV-2 & Influenza A/B test (+)	165	9	174	<b>97.1 (93.3, 98.7)</b>	<b>99.1 (98.2, 99.5)</b>
Cobas Liat SARS-CoV-2 & Influenza A/B test (-)	5	961	966		
<b>Total</b>	<b>170</b>	<b>970</b>	<b>1,140</b>		
<b>Nasopharyngeal</b>					
Cobas Liat SARS-CoV-2 & Influenza A/B test (+)	162	5	167	<b>96.4 (92.4, 98.4)</b>	<b>99.4 (98.7, 99.8)</b>
Cobas Liat SARS-CoV-2 & Influenza A/B test (-)	6	896	902		
<b>Total</b>	<b>168</b>	<b>901</b>	<b>1,069</b>		

535

536 Abbreviations: CI, Score confidence interval; NPA, negative percent agreement; PPA, positive percent agreement; SARS-CoV-2, severe acute  
537 respiratory syndrome coronavirus 2.

538 <sup>a</sup>The Cobas SARS-CoV-2 & Influenza A/B nucleic acid test for use on the Cobas Liat system is herein referred to as the Cobas Liat SARS-CoV-2  
539 & Influenza A/B test.

## References

1. Mathieu E, Ritchie H, Rod  s-Guirao L, Appel C, Giattino C, Hasell J, Macdonald B, Dattani S, Beltekian D, Ortiz-Ospina E, Roser M. 2020. Coronavirus pandemic (COVID-19). <https://ourworldindata.org/coronavirus>. Accessed Mar 06, 2024.
2. Ahmad FB, Cisewski JA, Xu J, Anderson RN. 2023. COVID-19 Mortality Update - United States, 2022. MMWR Morb Mortal Wkly Rep 72:493  496.
3. Meyerowitz EA, Scott J, Richterman A, Male V, Cevik M. 2023. Clinical course and management of COVID-19 in the era of widespread population immunity. Nat Rev Microbiol 22:75  88.
4. Antinori A, Bausch-Jurken M. 2023. The burden of COVID-19 in the immunocompromised patient: implications for vaccination and needs for the future. J Infect Dis 228:S4  S12.
5. Wiemken TL, Khan F, Puzniak L, Yang W, Simmering J, Polgreen P, Nguyen JL, Jodar L, McLaughlin JM. 2023. Seasonal trends in COVID-19 cases, hospitalizations, and mortality in the United States and Europe. Sci Rep 13:3886.
6. Moriyama M, Hugentobler WJ, Iwasaki A. 2020. Seasonality of Respiratory Viral Infections. Annu Rev Virol 7:83  101.
7. World Health Organization. 2024. Coronavirus disease (COVID-19): similarities and differences between COVID-19 and influenza. <https://www.who.int/news-room/questions-and-answers/item/coronavirus-disease-covid-19-similarities-and-differences-with-influenza>. Accessed Aug 05, 2024.

- 564 8. Baldanti F, Ganguly NK, Wang G, Möckel M, O'Neill LA, Renz H, Dos Santos  
565 Ferreira CE, Tateda K, Van Der Pol B. 2022. Choice of SARS-CoV-2 diagnostic  
566 test: challenges and key considerations for the future. Crit Rev Clin Lab Sci  
567 59:445–459.
- 568 9. Hayden MK, Hanson KE, Englund JA, Lee MJ, Loeb M, Lee F, Morgan DJ, Patel  
569 R, El Mikati IK, Iqneibi S, Alabed F, Amarin JZ, Mansour R, Patel P, Falck-Ytter  
570 Y, Morgan RL, Murad MH, Sultan S, Bhimraj A, Mustafa RA. 2023. The  
571 Infectious Diseases Society of America guidelines on the diagnosis of  
572 coronavirus disease 2019 (COVID-19): molecular diagnostic testing. Clin  
573 Infect Dis doi:10.1093/cid/ciad646.
- 574 10. Katzenschlager S, Brümmer LE, Schmitz S, Tolle H, Manten K, Gaeddert M,  
575 Erdmann C, Lindner A, Tobian F, Grilli M, Pollock NR, Macé A, Erkosar B,  
576 Carmona S, Ongarello S, Johnson CC, Sacks JA, Denkinger CM, Yerlikaya S.  
577 2023. Comparing SARS-CoV-2 antigen-detection rapid diagnostic tests for  
578 COVID-19 self-testing/self-sampling with molecular and professional-use  
579 tests: a systematic review and meta-analysis. Sci Rep 13:21913.
- 580 11. Tolan NV, Horowitz GL. 2022. Clinical diagnostic point-of-care molecular  
581 assays for SARS-CoV-2. Clin Lab Med 42:223–236.
- 582 12. Shirley JD, Bennett SA, Binnicker MJ. 2023. Current regulatory landscape for  
583 viral point-of-care testing in the United States. J Clin Virol 164:105492.
- 584 13. Fragkou PC, Moschopoulos CD, Dimopoulou D, Ong DSY, Dimopoulou K,  
585 Nelson PP, Schweitzer VA, Janocha H, Karofylakis E, Papathanasiou KA,  
586 Tsiordras S, De Angelis G, Thölken C, Sanguinetti M, Chung HR, Skevaki C.  
587 2023. Performance of point-of care molecular and antigen-based tests for

588 SARS-CoV-2: a living systematic review and meta-analysis. Clin Microbiol  
589 Infect 29:291–301.

590 14. Bigio J, MacLean EL, Das R, Sulis G, Kohli M, Berhane S, Dinnes J, Deeks JJ,  
591 Brümmer LE, Denkinger CM, Pai M. 2023. Accuracy of package inserts of  
592 SARS-CoV-2 rapid antigen tests: a secondary analysis of manufacturer versus  
593 systematic review data. Lancet Microbe 4:e875–e882.

594 15. Wang X, Li Y, O'Brien KL, Madhi SA, Widdowson MA, Byass P, Omer SB, Abbas  
595 Q, Ali A, Amu A, Azziz-Baumgartner E, Bassat Q, Abdullah Brooks W, Chaves  
596 SS, Chung A, Cohen C, Echavarria M, Fasce RA, Gentile A, Gordon A, Groome  
597 M, Heikkinen T, Hirve S, Jara JH, Katz MA, Khuri-Bulos N, Krishnan A, de Leon  
598 O, Lucero MG, McCracken JP, Mira-Iglesias A, Moisi JC, Munywoki PK,  
599 Ourohiré M, Polack FP, Rahi M, Rasmussen ZA, Rath BA, Saha SK, Simões EA,  
600 Sotomayor V, Thamthitiwat S, Treurnicht FK, Wamukoya M, Yoshida LM, Zar  
601 HJ, Campbell H, Nair H. 2020. Global burden of respiratory infections  
602 associated with seasonal influenza in children under 5 years in 2018: a  
603 systematic review and modelling study. Lancet Glob Health 8:e497–e510.

604 16. Paget J, Spreeuwenberg P, Charu V, Taylor RJ, Iuliano AD, Bresee J, Simonsen  
605 L, Viboud C. 2019. Global mortality associated with seasonal influenza  
606 epidemics: new burden estimates and predictors from the GLaMOR Project. J  
607 Glob Health 9:020421.

608 17. GBD 2017 Influenza Collaborators. 2019. Mortality, morbidity, and  
609 hospitalisations due to influenza lower respiratory tract infections, 2017: an  
610 analysis for the Global Burden of Disease Study 2017. Lancet Respir Med  
611 7:69–89.



- 612 18. Maleki F, Welch V, Lopez SMC, Cane A, Langer J, Enstone A, Markus K, Wright  
613 O, Hewitt N, Whittle I. 2023. Understanding the global burden of influenza in  
614 adults aged 18-64 years: a systematic literature review from 2012 to 2022.  
615 Adv Ther 40:4166–4188.
- 616 19. Gibson J, Schechter-Perkins EM, Mitchell P, Mace S, Tian Y, Williams K, Luo R,  
617 Yen-Lieberman B. 2017. Multi-center evaluation of the Cobas® Liat®  
618 Influenza A/B & RSV assay for rapid point of care diagnosis. J Clin Virol 95:5–  
619 9.
- 620 20. Young S, Phillips J, Griego-Fullbright C, Wagner A, Jim P, Chaudhuri S, Tang S,  
621 Sickler J. 2020. Molecular point-of-care testing for influenza A/B and  
622 respiratory syncytial virus: comparison of workflow parameters for the ID Now  
623 and Cobas Liat systems. J Clin Pathol 73:328–334.
- 624 21. Azar MM, Landry ML. 2018. Detection of influenza A and B viruses and  
625 respiratory syncytial virus by use of Clinical Laboratory Improvement  
626 Amendments of 1988 (CLIA)-waived point-of-care assays: a paradigm shift to  
627 molecular tests. J Clin Microbiol 56:e00367-18.
- 628 22. Melchers WJG, Kuijpers J, Sickler JJ, Rahamat-Langendoen J. 2017. Lab-in-a-  
629 tube: real-time molecular point-of-care diagnostics for influenza A and B using  
630 the Cobas® Liat® system. J Med Virol 89:1382–1386.
- 631 23. Uyeki TM, Bernstein HH, Bradley JS, Englund JA, File TM, Fry AM, Gravenstein  
632 S, Hayden FG, Harper SA, Hirshon JM, Ison MG, Johnston BL, Knight SL,  
633 McGeer A, Riley LE, Wolfe CR, Alexander PE, Pavia AT. 2019. Clinical practice  
634 guidelines by the Infectious Diseases Society of America: 2018 update on

- 635 diagnosis, treatment, chemoprophylaxis, and institutional outbreak
- 636 management of seasonal influenza. Clin Infect Dis 68:895–902.
- 637 24. Berry L, Lansbury L, Gale L, Carroll AM, Lim WS. 2020. Point of care testing of
- 638 Influenza A/B and RSV in an adult respiratory assessment unit is associated
- 639 with improvement in isolation practices and reduction in hospital length of
- 640 stay. J Med Microbiol 69:697–704.
- 641 25. Rahamat-Langendoen J, Groenewoud H, Kuijpers J, Melchers WJG, van der
- 642 Wilt GJ. 2019. Impact of molecular point-of-care testing on clinical
- 643 management and in-hospital costs of patients suspected of influenza or RSV
- 644 infection: a modeling study. J Med Virol 91:1408–1414.
- 645 26. Mikamo H, Koizumi Y, Yamagishi Y, Asai N, Miyazono Y, Shinbo T, Horie M,
- 646 Togashi K, Robbins EM, Hirotsu N. 2022. Comparing the Cobas Influenza A/B
- 647 Nucleic acid test for use on the Cobas Liat System (Liat) with rapid antigen
- 648 tests for clinical management of Japanese patients at the point of care. PLoS
- 649 One 17:e0276099.
- 650 27. Roche Molecular Systems Inc. 2021. Cobas® Liat® System User Guide.
- 651 28. Roche Molecular Systems Inc. 2021. Instructions for use. Cobas® SARS-CoV-
- 652 2. Qualitative assay for use on the Cobas® 6800/8800 Systems. P/N:
- 653 09179917001-07EN.
- 654 29. Roche Molecular Systems Inc. 2021. Instructions for use. Cobas® SARS-CoV-
- 655 2 & Influenza A/B. Qualitative assay for use on the Cobas® 6800/8800
- 656 Systems. P/N: 09233474190.

- 657 30. Mostafa HH, Hardick J, Morehead E, Miller JA, Gaydos CA, Manabe YC. 2020.  
658 Comparison of the analytical sensitivity of seven commonly used commercial  
659 SARS-CoV-2 automated molecular assays. J Clin Virol 130:104578.
- 660 31. Copan Diagnostics Inc. 2020. Instructions for use. FLOQSwabs. HPC217  
661 Rev.00 Date 2020.10. [https://www.copanusa.com/wp-](https://www.copanusa.com/wp-content/uploads/2021/03/HPC217-PI-FLOQSWAB-NO-CE-REV.00-2020.10.pdf)  
662 [content/uploads/2021/03/HPC217-PI-FLOQSWAB-NO-CE-REV.00-2020.10.pdf](https://www.copanusa.com/wp-content/uploads/2021/03/HPC217-PI-FLOQSWAB-NO-CE-REV.00-2020.10.pdf).  
663 Accessed Aug 5, 2024.
- 664 32. Centers for Disease Control and Prevention. 2023. 2021-2022 flu season  
665 summary. [https://www.cdc.gov/flu/season/faq-flu-season-2021-](https://www.cdc.gov/flu/season/faq-flu-season-2021-2022.htm#print)  
666 [2022.htm#print](https://www.cdc.gov/flu/season/faq-flu-season-2021-2022.htm#print). Accessed Aug 05, 2024.
- 667 33. Dzung A, Cheng PF, Stoffel C, Tastanova A, Turko P, Levesque MP, Bosshard  
668 PP. 2021. Prolonged unfrozen storage and repeated freeze-thawing of SARS-  
669 CoV-2 patient samples have minor effects on SARS-CoV-2 detectability by RT-  
670 PCR. J Mol Diagn 23:691–697.
- 671 34. Roche Molecular Systems Inc. 2020. Instructions for use. Cobas® SARS-CoV-  
672 2 & Influenza A/B. Nucleic acid test for use on the Cobas® Liat® System.  
673 P/N: 09211101190.
- 674 35. Hologic. 2020. Instructions for use. Aptima® SARS-CoV-2 Assay (Panther®  
675 System).
- 676 36. Wilson E. 1927. Probable inference, the law of succession, and statistical  
677 inference. J Am Stat Assoc 22:209–212.
- 678 37. Akashi Y, Horie M, Kiyotaki J, Takeuchi Y, Togashi K, Adachi Y, Ueda A, Notake  
679 S, Nakamura K, Terada N, Kurihara Y, Kiyasu Y, Suzuki H. 2022. Clinical

680 performance of the cobas Liat SARS-CoV-2 & Influenza A/B Assay in nasal  
681 samples. Mol Diagn Ther 26:323–331.

682 38. Hansen G, Marino J, Wang ZX, Beavis KG, Rodrigo J, Labog K, Westblade LF,  
683 Jin R, Love N, Ding K, Garg S, Huang A, Sickler J, Tran NK. 2021. Clinical  
684 performance of the point-of-care Cobas Liat for detection of SARS-CoV-2 in 20  
685 minutes: a multicenter study. J Clin Microbiol 59:e02811-20.

686 39. Park K, Sung H, Kim MN. 2023. Evaluation of the cobas Liat detection test for  
687 SARS-CoV-2 and influenza viruses following the emergence of the SARS-CoV-2  
688 Omicron variant. Diagn Microbiol Infect Dis 105:115891.

689 40. Er TK, Chou YC, Chen SY, Huang JW. 2021. Rapid cobas Liat SARS-CoV-2  
690 assay in comparison with the laboratory-developed real-time RT-PCR test. Clin  
691 Lab 67.

692 41. Matic N, Lawson T, Ritchie G, Lowe CF, Romney MG. 2024. Testing the limits  
693 of multiplex respiratory virus assays for SARS-CoV-2 at high cycle threshold  
694 values: Comparative performance of Cobas 6800/8800 SARS-CoV-2 &  
695 Influenza A/B, Xpert Xpress SARS-CoV-2/Flu/RSV, and Cobas Liat SARS-CoV-2  
696 & Influenza A/B. J Assoc Med Microbiol Infect Dis Can 8:328-335.

697 42. Lee RA, Herigon JC, Benedetti A, Pollock NR, Denkinger CM. 2021.  
698 Performance of saliva, oropharyngeal swabs, and nasal swabs for SARS-CoV-2  
699 molecular detection: a systematic review and meta-analysis. J Clin Microbiol  
700 59:e02881-20.

701 43. Therchilsen JH, von Buchwald C, Koch A, Dam Nielsen S, Rasmussen DB,  
702 Thudium RF, Kirkby NS, Raaschou-Pedersen DET, Bundgaard JS, Iversen K,  
703 Bundgaard H, Todsén T. 2020. Self-collected versus healthcare worker-

- 704 collected swabs in the diagnosis of severe acute respiratory syndrome
- 705 coronavirus 2. *Diagnostics* 10:678.
- 706 44. Craney AR, Velu PD, Satlin MJ, Fauntleroy KA, Callan K, Robertson A, La Spina
- 707 M, Lei B, Chen A, Alston T, Rozman A, Loda M, Rennert H, Cushing M,
- 708 Westblade LF. 2020. Comparison of two high-throughput reverse
- 709 transcription-PCR systems for the detection of severe acute respiratory
- 710 syndrome coronavirus 2. *J Clin Microbiol* 58:e00890-20.
- 711 45. Buchta C, Zeichhardt H, Badrick T, Coucke W, Wojtalewicz N, Griesmacher A,
- 712 Aberle SW, Schellenberg I, Jacobs E, Nordin G, Schweiger C, Schwenoha K,
- 713 Lupp PB, Gassner UM, Wagner T, Kammel M. 2023. Classification of "near-
- 714 patient" and "point-of-care" SARS-CoV-2 nucleic acid amplification test
- 715 systems and a first approach to evaluate their analytical independence of
- 716 operator activities. *J Clin Virol* 165:105521.
- 717 46. May L, Robbins EM, Canchola JA, Chugh K, Tran NK. 2023. A study to assess
- 718 the impact of the Cobas point-of-care RT-PCR assay (SARS-CoV-2 and
- 719 Influenza A/B) on patient clinical management in the emergency department
- 720 of the University of California at Davis Medical Center. *J Clin Virol* 168:105597.
- 721 47. Jian MJ, Chung HY, Chang CK, Lin JC, Yeh KM, Chen CW, Li SY, Hsieh SS, Liu
- 722 MT, Yang JR, Tang SH, Perng CL, Chang FY, Shang HS. 2021. Clinical
- 723 comparison of three sample-to-answer systems for detecting SARS-CoV-2 in
- 724 B.1.1.7 lineage emergence. *Infect Drug Resist* 14:3255–3261.
- 725 48. Perlitz B, Slagman A, Hitzek J, Riedlinger D, Möckel M. 2021. Point-of-care
- 726 testing for influenza in a university emergency department: a prospective
- 727 study. *Influenza Other Respir Viruses* 15:608–617.

728 49. Yan X, Li K, Lei Z, Luo J, Wang Q, Wei S. 2023. Prevalence and associated  
729 outcomes of coinfection between SARS-CoV-2 and influenza: a systematic  
730 review and meta-analysis. *Int J Infect Dis* 136:29–36.

731